Cite
HARVARD Citation
Phillips, A. et al. (2020). Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines. Lancet. 7 (3), pp. e193-e200. [Online].